Christopher R Triggle

List of Publications by Year
in descending order

121 papers	6,950 citations	61857 43 h-index	66788 78 g-index
122 all docs	122 docs citations	122 times ranked	8660 citing authors

#	Article	IF	Citations
1	Metformin: An Old Drug for the Treatment of Diabetes but a New Drug for the Protection of the Endothelium. Medical Principles and Practice, 2015, 24, 401-415.	1.1	1,060
2	A Review of the Progress and Challenges of Developing a Vaccine for COVID-19. Frontiers in Immunology, 2020, 11, 585354.	2.2	384
3	Varying Extracellular [K+]. Journal of Cardiovascular Pharmacology, 1993, 21, 423-429.	0.8	252
4	FGF21 Maintains Glucose Homeostasis by Mediating the Cross Talk Between Liver and Brain During Prolonged Fasting. Diabetes, 2014, 63, 4064-4075.	0.3	217
5	Fibroblast Growth Factor 21 Prevents Atherosclerosis by Suppression of Hepatic Sterol Regulatory Element-Binding Protein-2 and Induction of Adiponectin in Mice. Circulation, 2015, 131, 1861-1871.	1.6	217
6	Metformin modulates hyperglycaemiaâ€induced endothelial senescence and apoptosis through <scp>SIRT1</scp>. British Journal of Pharmacology, 2014, 171, 523-535.	2.7	193
7	The endothelium: influencing vascular smooth muscle in many ways. Canadian Journal of Physiology and Pharmacology, 2012, 90, 713-738.	0.7	188
8	Cellular basis of endothelial dysfunction in small mesenteric arteries from spontaneously diabetic (db/db â^'/â^') mice: role of decreased tetrahydrobiopterin bioavailability. British Journal of Pharmacology, 2002, 136, 255-263.	2.7	164
9	Endothelium-derived relaxing factors: A focus on endothelium-derived hyperpolarizing factor(s). Canadian Journal of Physiology and Pharmacology, 2001, 79, 443-470.	0.7	146
10	2-Furoyl-LIGRLO-amide: A Potent and Selective Proteinase-Activated Receptor 2 Agonist. Journal of Pharmacology and Experimental Therapeutics, 2004, 309, 1124-1131.	1.3	128
11	A Comprehensive Review of Viral Characteristics, Transmission, Pathophysiology, Immune Response, and Management of SARS-CoV-2 and COVID-19 as a Basis for Controlling the Pandemic. Frontiers in Immunology, 2021, 12, 631139.	2.2	117
12	Exercise Alleviates Obesity-Induced Metabolic Dysfunction via Enhancing FGF21 Sensitivity in Adipose Tissues. Cell Reports, 2019, 26, 2738-2752.e4.	2.9	115
13	Selective cyclo-oxygenase-2 inhibition with celecoxib elevates blood pressure and promotes leukocyte adherence. British Journal of Pharmacology, 2000, 129, 1423-1430.	2.7	112
14	A role for nitroxyl (HNO) as an endotheliumâ€derived relaxing and hyperpolarizing factor in resistance arteries. British Journal of Pharmacology, 2009, 157, 540-550.	2.7	110
15	Vascular smooth muscle relaxation mediated by nitric oxide donors: a comparison with acetylcholine, nitric oxide andnitroxyl ion. British Journal of Pharmacology, 2001, 134, 463-472.	2.7	108
16	A Critical Review of the Evidence That Metformin Is a Putative Anti-Aging Drug That Enhances Healthspan and Extends Lifespan. Frontiers in Endocrinology, 2021, 12, 718942.	1.5	107
17	Endothelial Dysfunction in Diabetes Mellitus: Possible Involvement of Endoplasmic Reticulum Stress?. Experimental Diabetes Research, 2012, 2012, 1-14.	3.8	98
18	Endothelial cell dysfunction and the vascular complications associated with type 2 diabetes: assessing the health of the endothelium. Vascular Health and Risk Management, 2005, 1, 55-71.	1.0	95

#	Article	IF	Citations
19	Endothelial dysfunction in the streptozotocin-induced diabetic apoE-deficient mouse. British Journal of Pharmacology, 2005, 146, 1110-1118.	2.7	92
20	Metformin: Is it a drug for all reasons and diseases?. Metabolism: Clinical and Experimental, 2022, 133, 155223.	1.5	92
21	The Endothelium in Health and Disease-A Target for Therapeutic Intervention.. Journal of Smooth Muscle Research, 2003, 39, 249-267.	0.7	90
22	Oxidative stress and increased eNOS and NADPH oxidase expression in mouse microvessel endothelial cells. Journal of Cellular Physiology, 2007, 212, 682-689.	2.0	89
23	Endothelial dysfunction in diabetes: multiple targets for treatment. Pflugers Archiv European Journal of Physiology, 2010, 459, 977-994.	1.3	89
24	Chronic oral supplementation with sepiapterin prevents endothelial dysfunction and oxidative stress in small mesenteric arteries from diabetic (db/db) mice. British Journal of Pharmacology, 2003, 140, 701-706.	2.7	86
25	Enhanced vascular reactivity of small mesenteric arteries from diabetic mice is associated with enhanced oxidative stress and cyclooxygenase products. British Journal of Pharmacology, 2005, 144, 953-960.	2.7	84
26	A review of endothelial dysfunction in diabetes: a focus on the contribution of a dysfunctional eNOS. Journal of the American Society of Hypertension, 2010, 4, 102-115.	2.3	84
27	Hyperglycaemic impairment of PAR2-mediated vasodilation: Prevention by inhibition of aortic endothelial sodium-glucose-co-Transporter-2 and minimizing oxidative stress. Vascular Pharmacology, 2018, 109, 56-71.	1.0	84
28	Metformin is not just an antihyperglycaemic drug but also has protective effects on the vascular endothelium. Acta Physiologica, 2017, 219, 138-151.	1.8	83
29	Molecular Interplay between microRNA-34a and Sirtuin1 in Hyperglycemia-Mediated Impaired Angiogenesis in Endothelial Cells: Effects of Metformin. Journal of Pharmacology and Experimental Therapeutics, 2016, 356, 314-323.	1.3	78
30	NO/PGI2 -independent vasorelaxation and the cytochrome P450 pathway in rabbit carotid artery. British Journal of Pharmacology, 1997, 120, 695-701.	2.7	76
31	Multiple mechanisms of vascular smooth muscle relaxation by the activation of Proteinase-Activated Receptor 2 in mouse mesenteric arterioles. British Journal of Pharmacology, 2002, 135, 155-169.	2.7	76
32	Endothelium-derived reactive oxygen species: their relationship to endothelium-dependent hyperpolarization and vascular tone. Canadian Journal of Physiology and Pharmacology, 2003, 81, 1013-1028.	0.7	76
33	Roles of calcium-activated and voltage-gated delayed rectifier potassium channels in endothelium-dependent vasorelaxation of the rabbit middle cerebral artery. British Journal of Pharmacology, 1998, 123, 821-832.	2.7	66
34	COVID-19: Learning from Lessons To Guide Treatment and Prevention Interventions. MSphere, 2020, 5, .	1.3	66
35	Catalase has negligible inhibitory effects on endothelium-dependent relaxations in mouse isolated aorta and small mesenteric artery. British Journal of Pharmacology, 2003, 140, 1193-1200.	2.7	63
36	Increased oxidative stress in the streptozotocin-induced diabetic apoE-deficient mouse: Changes in expression of NADPH oxidase subunits and eNOS. European Journal of Pharmacology, 2007, 561, 121-128.	1.7	62

#	Article	IF	Citations
37	Metformin: The Answer to Cancer in a Flower? Current Knowledge and Future Prospects of Metformin as an Anti-Cancer Agent in Breast Cancer. Biomolecules, 2019, 9, 846.	1.8	60
38	Vasorelaxant effects of a nitric oxide-releasing aspirin derivative in normotensive and hypertensive rats. British Journal of Pharmacology, 2001, 133, 1314-1322.	2.7	58
39	Cardiovascular impact of drugs used in the treatment of diabetes. Therapeutic Advances in Chronic Disease, 2014, 5, 245-268.	1.1	54
40	Dual endothelium-dependent vascular activities of proteinase-activated receptor-2-activating peptides: evidence for receptor heterogeneity. British Journal of Pharmacology, 1998, 123, 1434-1440.	2.7	52
41	Comparison of the pharmacological properties of EDHF-mediated vasorelaxation in guinea-pig cerebral and mesenteric resistance vessels. British Journal of Pharmacology, 2000, 130, 1983-1991.	2.7	52
42	Pharmacological characteristics of endothelium-derived hyperpolarizing factor-mediated relaxation of small mesenteric arteries from db/db mice. European Journal of Pharmacology, 2006, 551, 98-107.	1.7	48
43	Tetrahydrobiopterin improves endothelial function in human saphenous veins. Journal of Thoracic and Cardiovascular Surgery, 2000, 120, 668-671.	0.4	46
44	Endothelium-dependent contractile actions of proteinase-activated receptor-2-activating peptides in human umbilical vein: release of a contracting factor via a novel receptor. British Journal of Pharmacology, 1998, 125, 1445-1454.	2.7	44
45	What is the future of peer review? Why is there fraud in science? Is plagiarism out of control? Why do scientists do bad things? Is it all a case of: "all that is necessary for the triumph of evil is that good men do nothing"?. Vascular Health and Risk Management, 2007, 3, 39-53.	1.0	44
46	Endothelium-Derived Hyperpolarizing Factor: Is There A Novel Chemical Mediator?. Clinical and Experimental Pharmacology and Physiology, 2002, 29, 153-160.	0.9	42
47	Novel role for K+-dependent Na+/Ca2+ exchangers in regulation of cytoplasmic free Ca2+ and contractility in arterial smooth muscle. American Journal of Physiology - Heart and Circulatory Physiology, 2006, 291, H1226-H1235.	1.5	42
48	Metformin improves endothelial function in aortic tissue and microvascular endothelial cells subjected to diabetic hyperglycaemic conditions. Biochemical Pharmacology, 2015, 98, 412-421.	2.0	40
49	Involvement of nitrosothiols, nitric oxide and voltage-gated K+ channels in photorelaxation of vascular smooth muscle. European Journal of Pharmacology, 1998, 347, 215-221.	1.7	38
50	Widespread vascular production of C-reactive protein (CRP) and a relationship between serum CRP, plaque CRP and intimal hypertrophy. Atherosclerosis, 2007, 191, 175-181.	0.4	37
51	Proteinase-Activated Receptor-2 (PAR2): Vascular Effects of a PAR2-Derived Activating Peptide via a Receptor Different than PAR2. Journal of Pharmacology and Experimental Therapeutics, 2002, 303, 985-992.	1.3	36
52	Why the endothelium? The endothelium as a target to reduce diabetes-associated vascular disease. Canadian Journal of Physiology and Pharmacology, 2020, 98, 415-430.	0.7	36
53	Antihypertensive properties of a nitric oxide-releasing naproxen derivative in two-kidney, one-clip rats. American Journal of Physiology - Heart and Circulatory Physiology, 2000, 279, H528-H535.	1.5	35
54	Hyperpolarization of murine small caliber mesenteric arteries by activation of endothelial proteinase-activated receptor 2. Canadian Journal of Physiology and Pharmacology, 2004, 82, 1103-1112.	0.7	35

#	Article	IF	Citations
55	Cyclic GMP-dependent and cyclic GMP-independent actions of nitric oxide on the renal afferent arteriole. British Journal of Pharmacology, 1998, 125, 563-569.	2.7	34
56	Metformin represses glucose starvation induced autophagic response in microvascular endothelial cells and promotes cell death. Biochemical Pharmacology, 2017, 132, 118-132.	2.0	34
57	Interactions of nitric oxide synthase inhibitors and dexamethasone with Î±â€adrenoceptorâ€mediated responses in rat aorta. British Journal of Pharmacology, 1993, 109, 495-501.	2.7	33
58	The effects of perfusion rate and N^Gâ€nitroâ€Lâ€arginine methyl ester on cirazolineâ€and KClâ€induced responses in the perfused mesenteric arterial bed of rats. British Journal of Pharmacology, 1994, 111, 13-20.	2.7	32
59	Effects of a Western diet versus high glucose on endothelium-dependent relaxation in murine micro- and macro-vasculature. European Journal of Pharmacology, 2008, 601, 111-117.	1.7	31
60	MicroRNA Signature and Cardiovascular Dysfunction. Journal of Cardiovascular Pharmacology, 2015, 65, 419-429.	0.8	31
61	Mechanism of bile salt vasoactivity: dependence on calcium channels in vascular smooth muscle. British Journal of Pharmacology, 1994, 112, 1209-1215.	2.7	30
62	A photosensitive vascular smooth muscle store of nitric oxide in mouse aorta: no dependence on expression of endothelial nitric oxide synthase. British Journal of Pharmacology, 2003, 138, 932-940.	2.7	28
63	The endothelium in health and disease: A discussion of the contribution of non-nitric oxide endothelium-derived vasoactive mediators to vascular homeostasis in normal vessels and in type II diabetes. Molecular and Cellular Biochemistry, 2004, 263, 21-27.	1.4	27
64	NO and the vasculature: where does it come from and what does it do?. Heart Failure Reviews, 2002, 7, 423-445.	1.7	26
65	Twenty-five years since the discovery of endothelium-derived relaxing factor (EDRF): does a dysfunctional endothelium contribute to the development of type 2 diabetes?. Canadian Journal of Physiology and Pharmacology, 2005, 83, 681-700.	0.7	26
66	The endothelium in compliance and resistance vessels. Frontiers in Bioscience - Scholar, 2011, S3, 730-744.	0.8	25
67	Nitrosothiol stores in vascular tissue: Modulation by ultraviolet light, acetylcholine and ionomycin. European Journal of Pharmacology, 2007, 560, 183-192.	1.7	24
68	Effects of oxidative and thermal stresses on stress granule formation in human induced pluripotent stem cells. PLoS ONE, 2017, 12, e0182059.	1.1	24
69	Vascular dysfunction in type 2 diabetic TallyHo mice: role for an increase in the contribution of PGH2/TxA2 receptor activation and cytochrome p450 productsThis paper is one of a selection of papers published in this Special Issue, entitled The Cellular and Molecular Basis of Cardiovascular Dysfunction, Dhalla 70th Birthday Tribute.. Canadian Journal of Physiology and Pharmacology, 2007, 85, 404-412.	0.7	23
70	Minimizing Hyperglycemia-Induced Vascular Endothelial Dysfunction by Inhibiting Endothelial Sodium-Glucose Cotransporter 2 and Attenuating Oxidative Stress: Implications for Treating Individuals With Type 2 Diabetes. Canadian Journal of Diabetes, 2019, 43, 510-514.	0.4	23
71	Novel endothelium-derived relaxing factors. Journal of Pharmacological and Toxicological Methods, 2000, 44, 441-452.	0.3	22
72	Endotheliumâ€dependent Vasodilation in Myogenically Active Mouse Skeletal Muscle Arterioles: Role of EDH and K⁺ Channels. Microcirculation, 2009, 16, 377-390.	1.0	22

#	Article	IF	Citations
73	Treatment with a Combination of Metformin and 2-Deoxyglucose Upregulates Thrombospondin-1 in Microvascular Endothelial Cells: Implications in Anti-Angiogenic Cancer Therapy. Cancers, 2019, 11, 1737.	1.7	21
74	Endothelial dysfunction in Type 2 diabetes correlates with deregulated expression of the tail-anchored membrane protein SLMAP. American Journal of Physiology - Heart and Circulatory Physiology, 2005, 289, H206-H211.	1.5	20
75	The vascular endothelium in diabetes: a practical target fordrug treatment?. Expert Opinion on Therapeutic Targets, 2005, 9, 101-117.	1.5	20
76	3D Tissue-Engineered Vascular Drug Screening Platforms: Promise and Considerations. Frontiers in Cardiovascular Medicine, 2022, 9, 847554.	1.1	20
77	COVID-19 Vaccines and Hyperglycemiaâ€"Is There a Need for Postvaccination Surveillance?. Vaccines, 2022, 10, 454.	2.1	20
78	The effects of Î±-adrenoceptor agonists on intracellular Ca2+ levels in freshly dispersed single smooth muscle cells from rat tail artery. British Journal of Pharmacology, 1993, 109, 1272-1275.	2.7	18
79	Calcium-activated potassium channel and connexin expression in small mesenteric arteries from eNOS-deficient (eNOSâˆ'/âˆ') and eNOS-expressing (eNOS+/+) mice. European Journal of Pharmacology, 2007, 560, 193-200.	1.7	17
80	Perivascular adipose tissue-derived relaxing factors: release by peptide agonists via proteinase-activated receptor-2 (PAR2) and non-PAR2 mechanisms. British Journal of Pharmacology, 2011, 164, 1990-2002.	2.7	17
81	Metformin Prevents Hyperglycemia-Associated, Oxidative Stress-Induced Vascular Endothelial Dysfunction: Essential Role for the Orphan Nuclear Receptor Human Nuclear Receptor 4A1 (Nur77). Molecular Pharmacology, 2021, 100, 428-455.	1.0	17
82	From Gutenberg to Open Science: An Unfulfilled Odyssey. Drug Development Research, 2017, 78, 3-23.	1.4	16
83	Hyperglycaemia disrupts conducted vasodilation in the resistance vasculature of db/db mice. Vascular Pharmacology, 2018, 103-105, 29-35.	1.0	15
84	Potent and PPARÎ±-independent anti-proliferative action of the hypolipidemic drug fenofibrate in VEGF-dependent angiosarcomas in vitro. Scientific Reports, 2019, 9, 6316.	1.6	15
85	Augmentation of endothelial function by endothelin antagonism in human saphenous vein conduits. Journal of Neurosurgery, 2001, 94, 281-286.	0.9	13
86	Nitric oxide, a possible mediator of 1,4â€dihydropyridineâ€induced photorelaxation of vascular smooth muscle. British Journal of Pharmacology, 1996, 118, 879-884.	2.7	12
87	Endothelin blockade potentiates endothelial protective effects of ace inhibitors in saphenous veins. Annals of Thoracic Surgery, 2002, 73, 1185-1188.	0.7	12
88	Defying the economists: a decrease in heart rate improves not only cardiac but also endothelial function. British Journal of Pharmacology, 2008, 154, 727-728.	2.7	12
89	Endothelial cell dysfunction in type I and II diabetes: The cellular basis for dysfunction. Drug Development Research, 2003, 58, 28-41.	1.4	11
90	Requiem for impact factors and high publication charges. Accountability in Research, 2022, 29, 133-164.	1.6	11

#	Article	IF	Citations
91	The early effects of elevated glucose on endothelial function as a target in the treatment of type 2 diabetes. Drugs of Today, 2007, 43, 815.	0.7	11
92	The endothelium in health and disease: a discussion of the contribution of non-nitric oxide endothelium-derived vasoactive mediators to vascular homeostasis in normal vessels and in type II diabetes. Molecular and Cellular Biochemistry, 2004, 263, 21-7.	1.4	11
93	Proteinaseâ€activated receptors 1 and 2 and the regulation of porcine coronary artery contractility: a role for distinct tyrosine kinase pathways. British Journal of Pharmacology, 2014, 171, 2413-2425.	2.7	10
94	A Nonthiazolidinedione Peroxisome Proliferator-Activated Receptor Î³ Agonist Reverses Endothelial Dysfunction in Diabetic (db/db-/-) Mice. Journal of Pharmacology and Experimental Therapeutics, 2006, 316, 364-370.	1.3	9
95	Novel Hantzsch 1,4-dihydropyridines to study the structure-function relationships of calcium channels and photoinduced relaxation. Drug Development Research, 1997, 42, 120-130.	1.4	8
96	Impact of currently used anti-diabetic drugs on myoendothelial communication. Current Opinion in Pharmacology, 2019, 45, 1-7.	1.7	8
97	Cardiovascular effects of CPU-23, a novel L-type calcium channel blocker with a unique molecular structure. British Journal of Pharmacology, 1997, 122, 1271-1278.	2.7	7
98	Matching Drug Metabolites from Non-Targeted Metabolomics to Self-Reported Medication in the Qatar Biobank Study. Metabolites, 2022, 12, 249.	1.3	7
99	Lack of involvement of endothelin-1 in angiotensin II-induced contraction of the isolated rat tail artery. British Journal of Pharmacology, 2000, 131, 1055-1064.	2.7	6
100	Cytochrome P450 Products and Arachidonic Acidâ€"Induced, Nonâ€"Store-Operated, Ca2+Entry in Cultured Bovine Endothelial Cells. Endothelium: Journal of Endothelial Cell Research, 2005, 12, 153-161.	1.7	6
101	Challenges in the Biomedical Research Enterprise in the 21st century: Antecedents in the writings of David Triggle. Biochemical Pharmacology, 2015, 98, 342-359.	2.0	6
102	Peroxynitrite Biology. , 2014, , 207-242.		6
103	The early effects of elevated glucose on endothelial function as a target in the treatment of type 2 diabetes. Timely Topics in Medicine Cardiovascular Diseases [electronic Resource], 2008, 12, E3.	0.1	5
104	Photosensitization of oesophageal smooth muscle by 3â€NO^{2â€} 1,4â€dihydropyridines: evidence for two cyclic GMPâ€dependent effector pathways. British Journal of Pharmacology, 1995, 116, 3293-3301.	2.7	4
105	The answer is not 42. Biochemical Pharmacology, 2015, 98, 327-334.	2.0	4
106	Calcium antagonizes the magnesiumâ€induced high affinity state of the hepatic vasopressin receptor for the agonist interaction. British Journal of Pharmacology, 1990, 100, 5-10.	2.7	3
107	Contribution of EDHF and the role of potassium channels in the regulation of vascular tone. Drug Development Research, 2003, 58, 81-89.	1.4	3
108	Pain control: What a pain!. Drug Development Research, 2001, 54, 117-117.	1.4	2

#	Article	IF	Citations
109	Searching for the physiological role and therapeutic potential of vascular proteinase-activated receptor-2 (PAR2). Drug Development Research, 2003, 60, 14-19.	1.4	2
110	Cardiovascular Pharmacology of CPU-23: A Novel Calcium Channel Blocker. Cardiovascular Drug Reviews, 1996, 14, 364-379.	4.4	1
111	The Contribution of d-Tubocurarineâ€"sensitive and Apamin-sensitive K-channels to EDHF-mediated Relaxation of Mesenteric Arteries From eNOSâˆ'/âˆ' Mice. Journal of Cardiovascular Pharmacology, 2012, 59, 413-425.	0.8	1
112	Endothelial Cell K+ Channels, Membrane Potential and the Release of Vasoactive Factors from the Vascular Endothelium. , 2001, , 667-689.		1
113	Biomedical Research in Canada. Drug Development Research, 1997, 42, 111-112.	1.4	0
114	Hyperglycaemic Impairment of PAR2-Mediated Vasodilatation: Prevention by Inhibition of SGLT2 and Minimizing Mitochondrial Dysfunction. Atherosclerosis Supplements, 2018, 32, 137.	1.2	0
115	Endothelium-Derived Hyperpolarizing Factor(s). Does it Exist and What Role Does it Play in the Regulation of Blood Flow?. Progress in Experimental Cardiology, 2004, , 341-348.	0.0	0
116	Proteinaseâ€activated receptors, PAR1 & PAR2, regulate porcine coronary contractility via tyrosine kinaseâ€MAPKinase signaling involving a cyclooxygenase (COX)â€1 product. FASEB Journal, 2013, 27, 880.2.	0.2	0
117	Metformin modulates hyperglycemiaâ€induced endothelial dysfunction through SIRT1. FASEB Journal, 2013, 27, lb612.	0.2	0
118	Inhibition of the Akt Kinase Down-regulates ERK, Bcl-2 and Survivin and Suppresses Proliferation and Survival of Murine VEGF-dependent Angiosarcoma Cells. , 2016, , .		0
119	Metformin Mediated Inhibition of the mTOR Pathway Promotes Death in Glucose Starved Micro-Vascular Endothelial Cells. , 2016, , .		0
120	Comparative Expression Profile of Organic Cation Transporters in Diabetes and Cancer: Effects of Metformin. , 2016, , .		0
121	Stress Granules as a possible regulator of pluripotent stem cell self renewal and differentaition. , 2018, , .		0